Advertisement

Topics

Crescendo Biologics Ltd Company Profile

01:26 EDT 22nd September 2018 | BioPortfolio

Crescendo Biologics will apply highly innovative antibody fragment technologies to the development of new targeted therapeutics. The Crescendo transgenic mouse platform under development has the potential to rapidly and predictably generate high-affinity human heavy chain antibodies that readily yield VH fragments that have no requirement for humanisation. This is combined with a powerful in vitro ribosome display technology which offers significant advantages over existing approaches in antibody optimisation. VH fragments provide great flexibility as a starting point for the development of new targeted therapeutics combining the specificity and binding affinity of antibodies with certain desirable characteristics of small molecules.


News Articles [542 Associated News Articles listed on BioPortfolio]

Crescendo Biologics out-licenses 'Humabody' asset to Zai Lab

Zai Lab and Crescendo Biologics have signed a licensing agreement under which Zai Lab will develop protein therapeutics for inflammatory indications.

Crescendo Biologics first major milestone in collaboration with Takeda reached

Crescendo Biologics Ltd, the developer of multifunctional biologics, including targeted T-cell engagers, announced that it has achieved the first major technical milestone under the terms of its colla...

Crescendo Biologics Ltd. Raises $70 Million in Series B Financing

Crescendo Biologics Ltd announced that it has completed a $70 million (€57 million) Series B financing. The funds will be used to advance the development of its lead programme, CB307, which stimulat...

Deals this week: Refuge Biotechnologies, Attenua, Crescendo Biologics

US-based Refuge Biotechnologies Inc has raised $25m in a series B funding round led by 3SBio and Sequoia China. The...Read More... The post Deals this week: Refuge Biotechnologies, Attenua, Crescendo ...

Zai acquires rights to Crescendo's psoriasis antibody

Zai Lab was granted exclusive worldwide rights to Crescendo Biologics' undisclosed antibody based on its Humabody platform.  -More- 

Crescendo Biologics Reaches Technical Milestone for a Second Target in Strategic Collaboration ...

Crescendo BiologicsDr Peter PackCEOTel:44 (0)1223 497140info@crescendobiologics.comorInstinctif PartnersMelanie Toyne-Sewell / Dr Christelle Kerouedan / Deborah BellTel:44 (0)20 7...

Crescendo hires ex-Roche R&D guru to develop T-cell technology

Backed with $70 million from a fundraising round earlier this year, UK biotech Crescendo Biologics has appointed a world-leading immuno-oncologist to its team. Dr Pavel Pisa is the UK-based company...

Funding round raises $70M for Crescendo

A round of Series B funding brought in $70 million for Crescendo Biologics.  -More- 

Drugs and Medications [3 Associated Drugs and Medications listed on BioPortfolio]

Standardized cat pelt [Jubilant HollisterStier LLC]

ALLERGENIC EXTRACT STANDARDIZED CAT PELT AP ACETONE PRECIPITATED

Standardized cat hair [Jubilant HollisterStier LLC]

ALLERGENIC EXTRACT STANDARDIZED CAT HAIR AP Acetone Precipitated

Cinryze [ViroPharma Biologics]

These highlights do not include all the information needed to use CINRYZE™ safely and effectively. See full prescribing information for CINRYZE.CINRYZE™ (C1 Esterase Inhibitor [Human]) For Intrave...

PubMed Articles [115 Associated PubMed Articles listed on BioPortfolio]

Biologics for pityriasis rubra pilaris treatment: a review of the literature.

Pityriasis rubra pilaris (PRP) is a rare inflammatory papulosquamous skin disease, often refractory to conventional therapies. The off-label use of biologics, such as anti-TNF, -IL-12/IL-23, -IL-17 ag...

Facilitated recruitment of mesenchymal stromal cells by bone marrow concentrate and platelet rich plasma.

Biologics containing growth factors are frequently used to enhance healing after musculoskeletal injuries. One mechanism of action is thought to be though the ability of biologics to induce homing and...

Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16,545 biologic-naïve patients from the French national health insurance database (SNIIRAM).

Long-term clinical effectiveness of biologics in psoriasis is needed.

Biologics Monitoring: Incongruity between Recommendations and Clinician Monitoring Trends.

Biologics are a commonly used treatment for moderate to severe psoriasis. Monitoring laboratory test overuse provide little definitive benefit to patients.

Dosing considerations for inhaled biologics.

The number of biologics in the therapeutic development pipeline is increasing including those delivered though inhalation (Morales, 2017; Fathe, 2016). Biologics comprise a broad variety of complex ma...

Clinical Trials [78 Associated Clinical Trials listed on BioPortfolio]

Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database

The patients included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health plan...

Golimumab Safety and Surveillance Program Using the Ingenix NHI Database

The participants included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health ...

Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease

"RUN-CD" is an investigator initiated "Non interventional Trial" on biologics in Crohn´s Disease (CD) patients in Germany with a prospective documentation of effectiveness in induction an...

Tight Control Dose Reductions of Biologics in Psoriasis Patients With Low Disease Activity

Rationale/hypothesis: Moderate-to-severe psoriasis can be treated with biologics. Objective To investigate whether the dose of biologics can be reduced in patients with psoriasis with sta...

Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis

To estimate the real-world effectiveness of approved biologics in subjects with moderate-to-severe plaque psoriasis who are either starting or switching biologic medication.

Companies [267 Associated Companies listed on BioPortfolio]

Crescendo Biologics Ltd

Crescendo Biologics will apply highly innovative antibody fragment technologies to the development of new targeted therapeutics. The Crescendo transgenic mouse platform under development has the p...

Crescendo Pharmaceuticals

Crescendo was formed by ALZA for the purpose of selecting and developing human pharmaceutical products (the "Crescendo Products") and commercializing such products, most likely through licensing to AL...

Crescendo Bioscience, Inc.

Crescendo Bioscience is a molecular diagnostics company focused in rheumatology and located in South San Francisco, CA. Crescendo Bioscience develops quantitative, objective, biol...

Crescendo Bioscience

Crescendo Bioscience is a molecular diagnostics company focused in rheumatology and located in South San Francisco, CA. Crescendo Bioscience is developing quantitative, objective,...

ABEC and WuXi Biologics

WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover d...

More Information about "Crescendo Biologics Ltd" on BioPortfolio

We have published hundreds of Crescendo Biologics Ltd news stories on BioPortfolio along with dozens of Crescendo Biologics Ltd Clinical Trials and PubMed Articles about Crescendo Biologics Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Crescendo Biologics Ltd Companies in our database. You can also find out about relevant Crescendo Biologics Ltd Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record